Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients.
We compared the response to protease inhibitor-containing highly active antiretroviral therapy in 175 HIV-1 treatment-naive patients harbouring subtype B versus non-B. No difference in the proportion of patients with viral loads below 400 copies/ml was observed at month 24. However, there was a significant difference in the median CD4 cell increase at month 24. Whether this is caused by viral or immune factors warrants further investigation.
De Wit
Stéphane
S
St Pierre University Hospital, Brussels, Belgium.
Boulmé
Ronan
R
Poll
Bénédicte
B
Schmit
Jean-Claude
JC
Clumeck
Nathan
N
D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D017320:HIV Protease Inhibitors / Q000276:immunology / Q000627:therapeutic use*; D015497:HIV-1 / Q000145:classification* / Q000276:immunology; D006801:Humans; D016896:Treatment Outcome; D019562:Viral Load
D017320:HIV Protease Inhibitors